Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The unexpected high prevalence of HBV subgenotype D4 in patients with chronic hepatitis B in Galicia, a northwestern Spanish region, reflects strong links with Latin America.
Trastoy R, Gonzalez-Alba JM, Soriano V, Rodriguez-Calviño JJ, de Mendoza C, Costa JJ, Cea M, Barbeito G, Corral O, Gómez-Gallego F, Pérez Del Molino ML, Carlos Galán J, Aguilera A. Trastoy R, et al. Among authors: cea m. J Clin Virol. 2022 Aug;153:105195. doi: 10.1016/j.jcv.2022.105195. Epub 2022 May 30. J Clin Virol. 2022. PMID: 35661583
Real-life validation of a sample pooling strategy for screening of hepatitis C.
Aguilera A, Fuentes A, Cea M, Carracedo R, Viñuela L, Ordóñez P, López-Fabal F, Sáez E, Cebrián R, Pérez-Revilla A, Pereira S, De Salazar A, García F. Aguilera A, et al. Among authors: cea m. Clin Microbiol Infect. 2023 Jan;29(1):112.e1-112.e4. doi: 10.1016/j.cmi.2022.09.006. Epub 2022 Sep 20. Clin Microbiol Infect. 2023. PMID: 36210627 Free article.
Assessment of performance and comparison of three commercial HDV RNA detection assays: implications for diagnosis and treatment monitoring.
Illescas-López M, Chaves-Blanco L, de Salazar A, Hernández-Febles M, Carracedo R, Lagarejos E, Fuentes A, Pereira S, Cea M, De La Iglesia A, Freyre C, Iborra A, Odero V, García-Barrionuevo A, Aguilera A, Pena MJ, García F. Illescas-López M, et al. Among authors: cea m. Front Cell Infect Microbiol. 2024 Jun 26;14:1422299. doi: 10.3389/fcimb.2024.1422299. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38988808 Free PMC article.
NAD+ METABOLISM RESTRICTION BOOSTS HIGH-DOSE MELPHALAN EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA.
Soncini D, Becherini P, Ladisa F, Ravera S, Chedere A, Gelli E, Giorgetti G, Martinuzzi C, Piacente F Dr, Mastracci L, Veneziano C Dr, Santamaria G Dr, Monacelli F, Ghanem MS, Cagnetta A, Guolo F Dr, Garibotto M, Aquino S, Passalacqua M, Bruzzone S, Bellotti A, Duchosal MA, Nahimana AA, Angelucci E, Nagasuma C Prof, Nencioni A, Lemoli RM, Cea M Prof. Soncini D, et al. Among authors: cea m prof. Blood Adv. 2024 Dec 11:bloodadvances.2024013425. doi: 10.1182/bloodadvances.2024013425. Online ahead of print. Blood Adv. 2024. PMID: 39661983
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease.
Riva C, Minetto P, Chies M, Vernarecci C, Colombo N, Rosellini S, Parodi A, Tedone E, Carminati E, Nurra C, Puglisi F, Frello M, Maio E, Ferro B, Zecchetti G, Fugazza G, Nozza P, Cea M, Lemoli RM, Guolo F. Riva C, et al. Among authors: cea m. Hematol Oncol. 2025 Jan;43(1):e70005. doi: 10.1002/hon.70005. Hematol Oncol. 2025. PMID: 39635952
Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis.
Gelli E, Martinuzzi C, Soncini D, Conticello C, Ladisa F, Giorgetti G, Truffelli D, Traverso I, Lai F, Guolo F, Miglino M, Cagnetta A, Laudisi A, Aquino S, Derudas D, Di Raimondo F, Coviello DA, Lemoli RM, Cea M. Gelli E, et al. Among authors: cea m. Sci Rep. 2024 Nov 26;14(1):29394. doi: 10.1038/s41598-024-79748-7. Sci Rep. 2024. PMID: 39592674 Free PMC article.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Furlan A, Cea M, Pavan L, Galli M, Clissa C, Mangiacavalli S, Cafro AM, Girlanda S, Patriarca F, Minotto C, Bertoldero G, Barilà G, Pascarella A, Lico A, Paolini R, Rabassi N, Pescosta N, Porrazzo M, De Sabbata G, Pompa A, Bega G, Cavallin S, Guidotti F, Marcatti M, Rupolo M, Belotti A, Gherlinzoni F, Zambello R. Furlan A, et al. Among authors: cea m. Cancer Med. 2024 Apr;13(7):e7071. doi: 10.1002/cam4.7071. Cancer Med. 2024. PMID: 38558233 Free PMC article.
155 results